DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Signos - 2 it's - 2 Ashley Capoot - 1 I've - 1 Dexcom - 1 Sharam Fouladgar - 1 you've - 1 Mercer - 1
Top related locs:
Mercer U.S Novo Europe Fouladgar America
Top related orgs:
CNBC - 2 Abbott Laboratories - 2 U.S . Food - 2 Drug Administration - 2 Dexcom Ventures - 2 Centers for Disease Control - 1 Bluetooth - 1 Cheyenne Ventures - 1

Search resuls for: "Dexcom Ventures"


2 mentions found


☆ Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like
  + stars: | 2024-03-09 | by ( Ashley Capoot | In | ) www.cnbc.com   time to read: +13 min
SignosFounded in 2018, Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms. But Signos' CGM system is meant for average consumers, so it is not intended for diabetes management. The Signos app walked me through the process step by step, offering a one-minute video and a series of GIFs I could watch. Another activity had me try and guess what I thought my glucose levels were at different points throughout the day. After eating a meal, I would often get a "Fast Rise" notification from my Signos app, which indicates that a glucose spike is occurring.
Persons: Ashley Capoot, I've, Signos, Dexcom, Sharam Fouladgar, you've, it's Organizations: CNBC, Abbott Laboratories, Centers for Disease Control, U.S . Food, Drug Administration, Dexcom Ventures, Bluetooth Locations: U.S, Mercer
☆ As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data
  + stars: | 2023-10-24 | by ( Ashley Capoot | ) www.cnbc.com   time to read: +6 min
Weight loss has always been big business, but it's exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. "Whether you have five pounds to lose or 100, we want to make sure we're able to help everybody," Sharam Fouladgar-Mercer, Signos' co-founder and CEO, told CNBC in an interview. Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments.
Persons: Signos, Mercer, it's, It's, GLP Organizations: Cheyenne Ventures, GV, Google Ventures, Dexcom Ventures, CNBC, Signos, U.S . Food, Drug Administration, Apple Watch, Abbott Laboratories, U.S, Novo Nordisk, Nordisk's Locations: Mercer, Novo, Europe, Fouladgar, America
0 next >>
Total: 2